Header Logo

Lei Duan

TitleAssociate Professor
InstitutionRush University, Rush Medical College
DepartmentAnatomy and Cell Biology
Address
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    My Scopus number is 55729339900
    My NIH COMMONS name is LDUAN1

    Research Areas:
    Basic and translational cancer research with a focus on understanding molecular mechanisms underlying cancer therapy resistance.

    My Faculty Profile at Rush University Medical Center:
    https://www.rushu.rush.edu/faculty/lei-duan-md

    My Laboratory:
    https://www.rushu.rush.edu/research/departmental-research/cell-molecular-medicine-research/laboratory-lei-duan-md

    My NCBI Bibliography:
    https://www.ncbi.nlm.nih.gov/myncbi/browse/collection/48065659/?sort=date&direction=descending

    My Scopus:
    https://www.scopus.com/authid/detail.uri?authorId=55729339900

    Education:
    MD, Shanghai Jiaotong University Medical School, China

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Duan L, Tadi MJ, O'Hara KM, Maki CG. Novel markers of MCL1 inhibitor sensitivity in triple-negative breast cancer cells. J Biol Chem. 2024 Jun; 300(6):107375. PMID: 38762181; PMCID: PMC11208921.
      Citations:    
    2. Duan L, Maki CG. Determinants of Aurora kinase B inhibitor sensitivity in small cell lung cancer. Transl Lung Cancer Res. 2024 Feb 29; 13(2):223-228. PMID: 38496702; PMCID: PMC10938090.
      Citations:    
    3. Duan L, Maki CG. Potential biomarkers for MCL1 inhibitor sensitivity. Cell Signal (Middlet). 2024; 2(1):144-147. PMID: 39802137; PMCID: PMC11720113.
      Citations:    
    4. Duan L, Tadi MJ, Maki CG. CSE1L is a negative regulator of the RB-DREAM pathway in p53 wild-type NSCLC and can be targeted using an HDAC1/2 inhibitor. Sci Rep. 2023 09 27; 13(1):16271. PMID: 37759078.
      Citations:    
    5. Duan L, Calhoun SJ, Perez RE, Macias V, Mir F, Gattuso P, Maki CG. Prolylcarboxypeptidase promotes IGF1R/HER3 signaling and is a potential target to improve endocrine therapy response in estrogen receptor positive breast cancer. Cancer Biol Ther. 2022 Dec 31; 23(1):1-10. PMID: 36332175.
      Citations:    
    6. Duan L, Perez RE, Calhoun S, Maki CG. Author Correction: RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC. Sci Rep. 2022 Mar 16; 12(1):4525. PMID: 35296774.
      Citations:    
    7. Duan L, Perez RE, Calhoun S, Maki CG. RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC. Sci Rep. 2022 01 20; 12(1):1049. PMID: 35058503.
      Citations:    
    8. Dong Q, Wang D, Li L, Wang J, Li Q, Duan L, Yin H, Wang X, Liu Y, Yuan G, Pan Y. Biochanin A Sensitizes Glioblastoma to Temozolomide by Inhibiting Autophagy. Mol Neurobiol. 2022 Feb; 59(2):1262-1272. PMID: 34981417.
      Citations:    
    9. Shim D, Duan L, Maki CG. Erratum: P53-regulated autophagy and its impact on drug resistance and cell fate. Cancer Drug Resist. 2021; 4(4):903. PMID: 35582378.
      Citations:    
    10. Duan L, Calhoun S, Shim D, Perez RE, Blatter LA, Maki CG. Fatty acid oxidation and autophagy promote endoxifen resistance and counter the effect of AKT inhibition in ER-positive breast cancer cells. J Mol Cell Biol. 2021 09 11; 13(6):433-444. PMID: 33755174.
      Citations:    
    11. Shim D, Duan L, Maki CG. P53-regulated autophagy and its impact on drug resistance and cell fate. Cancer Drug Resist. 2021; 4:85-95. PMID: 34532654.
      Citations:    
    12. Perez RE, Calhoun S, Shim D, Levenson VV, Duan L, Maki CG. Prolyl endopeptidase inhibitor Y-29794 blocks the IRS1-AKT-mTORC1 pathway and inhibits survival and in vivo tumor growth of triple-negative breast cancer. Cancer Biol Ther. 2020 11 01; 21(11):1033-1040. PMID: 33044914.
      Citations:    
    13. Duan L, Perez RE, Chastain PD, Mathew MT, Bijukumar DR, Maki CG. JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells. Oncogene. 2019 07; 38(28):5643-5657. PMID: 30967636.
      Citations:    
    14. Duan L, Perez RE, Maki CG. Alpha ketoglutarate levels, regulated by p53 and OGDH, determine autophagy and cell fate/apoptosis in response to Nutlin-3a. Cancer Biol Ther. 2019; 20(3):252-260. PMID: 30289354.
      Citations:    
    15. Duan L, Perez RE, Chen L, Blatter LA, Maki CG. p53 promotes AKT and SP1-dependent metabolism through the pentose phosphate pathway that inhibits apoptosis in response to Nutlin-3a. J Mol Cell Biol. 2018 08 01; 10(4):331-340. PMID: 29190376.
      Citations:    
    16. Davaadelger B, Perez RE, Zhou Y, Duan L, Gitelis S, Maki CG. The IGF-1R/AKT pathway has opposing effects on Nutlin-3a-induced apoptosis. Cancer Biol Ther. 2017 Nov 02; 18(11):895-903. PMID: 28696156.
      Citations:    
    17. Duan L, Maki CG. The IGF-1R/AKT pathway determines cell fate in response to p53. Transl Cancer Res. 2016 Dec; 5(6):664-675. PMID: 28966916.
      Citations:    
    18. Duan L, Ying G, Danzer B, Perez RE, Shariat-Madar Z, Levenson VV, Maki CG. The prolyl peptidases PRCP/PREP regulate IRS-1 stability critical for rapamycin-induced feedback activation of PI3K and AKT. J Biol Chem. 2014 Aug 01; 289(31):21694-705. PMID: 24936056.
      Citations:    
    19. Xu S, Zhuang X, Pan X, Zhang Z, Duan L, Liu Y, Zhang L, Ren X, Ding K. 1-Phenyl-4-benzoyl-1H-1,2,3-triazoles as orally bioavailable transcriptional function suppressors of estrogen-related receptor a. J Med Chem. 2013 Jun 13; 56(11):4631-40. PMID: 23656512.
      Citations:    
    20. Raja SM, Clubb RJ, Ortega-Cava C, Williams SH, Bailey TA, Duan L, Zhao X, Reddi AL, Nyong AM, Natarajan A, Band V, Band H. Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers. Cancer Biol Ther. 2011 Jan 15; 11(2):263-76. PMID: 21088503.
      Citations:    
    21. Duan L, Raja SM, Chen G, Virmani S, Williams SH, Clubb RJ, Mukhopadhyay C, Rainey MA, Ying G, Dimri M, Chen J, Reddi AL, Naramura M, Band V, Band H. Negative regulation of EGFR-Vav2 signaling axis by Cbl ubiquitin ligase controls EGF receptor-mediated epithelial cell adherens junction dynamics and cell migration. J Biol Chem. 2011 Jan 07; 286(1):620-33. PMID: 20940296.
      Citations:    
    22. Duan L, Chen G, Virmani S, Ying G, Raja SM, Chung BM, Rainey MA, Dimri M, Ortega-Cava CF, Zhao X, Clubb RJ, Tu C, Reddi AL, Naramura M, Band V, Band H. Distinct roles for Rho versus Rac/Cdc42 GTPases downstream of Vav2 in regulating mammary epithelial acinar architecture. J Biol Chem. 2010 Jan 08; 285(2):1555-68. PMID: 19826000.
      Citations:    
    23. Duan L, Yang J, Slaughter MM. Caffeine inhibition of ionotropic glycine receptors. J Physiol. 2009 Aug 15; 587(Pt 16):4063-75. PMID: 19564396.
      Citations:    
    24. Hou M, Duan L, Slaughter MM. Synaptic inhibition by glycine acting at a metabotropic receptor in tiger salamander retina. J Physiol. 2008 Jun 15; 586(12):2913-26. PMID: 18440992.
      Citations:    
    25. Reddi AL, Ying G, Duan L, Chen G, Dimri M, Douillard P, Druker BJ, Naramura M, Band V, Band H. Binding of Cbl to a phospholipase Cgamma1-docking site on platelet-derived growth factor receptor beta provides a dual mechanism of negative regulation. J Biol Chem. 2007 Oct 05; 282(40):29336-47. PMID: 17620338.
      Citations:    
    26. Dimri M, Naramura M, Duan L, Chen J, Ortega-Cava C, Chen G, Goswami R, Fernandes N, Gao Q, Dimri GP, Band V, Band H. Modeling breast cancer-associated c-Src and EGFR overexpression in human MECs: c-Src and EGFR cooperatively promote aberrant three-dimensional acinar structure and invasive behavior. Cancer Res. 2007 May 01; 67(9):4164-72. PMID: 17483327.
      Citations:    
    27. Singh AJ, Meyer RD, Navruzbekov G, Shelke R, Duan L, Band H, Leeman SE, Rahimi N. A critical role for the E3-ligase activity of c-Cbl in VEGFR-2-mediated PLCgamma1 activation and angiogenesis. Proc Natl Acad Sci U S A. 2007 Mar 27; 104(13):5413-8. PMID: 17372230.
      Citations:    
    28. Ghosh AK, Reddi AL, Rao NL, Duan L, Band V, Band H. Biochemical basis for the requirement of kinase activity for Cbl-dependent ubiquitinylation and degradation of a target tyrosine kinase. J Biol Chem. 2004 Aug 20; 279(34):36132-41. PMID: 15208330.
      Citations:    
    Duan's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (166)
    Explore
    _
    Co-Authors (5)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _